Literature DB >> 8224161

The protein kinase mos activates MAP kinase kinase in vitro and stimulates the MAP kinase pathway in mammalian somatic cells in vivo.

A R Nebreda1, C Hill, N Gomez, P Cohen, T Hunt.   

Abstract

The mos protooncogene encodes a serine/threonine protein kinase that is only expressed at significant levels in germ cells. Recombinant malE-mos protein (Xenopus mos protooncogene fused in frame to the maltose binding protein of E. coli) activates MAP kinase in cell-free extracts prepared from Xenopus oocytes and eggs. Here we show that malE-mos immunoprecipitates from Xenopus extracts phosphorylate and activate MAP kinase kinase in vitro, indicating that mos can function as a MAP kinase kinase kinase. Moreover, ectopic expression of mos in mammalian somatic cells, that lack any endogenous mos protein, triggers the activation of MAP kinase in vivo. These results identify the mos protooncogene as a direct activator of the MAP kinase pathway, with the potential to activate this kinase cascade even in cells where normally there is no expression of mos.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8224161     DOI: 10.1016/0014-5793(93)80401-f

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  30 in total

1.  A novel p34(cdc2)-binding and activating protein that is necessary and sufficient to trigger G(2)/M progression in Xenopus oocytes.

Authors:  I Ferby; M Blazquez; A Palmer; R Eritja; A R Nebreda
Journal:  Genes Dev       Date:  1999-08-15       Impact factor: 11.361

2.  The COOH-terminal domain of wild-type Cot regulates its stability and kinase specific activity.

Authors:  Maria Luisa Gándara; Pilar López; Raquel Hernando; José G Castaño; Susana Alemany
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

3.  Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase.

Authors:  A Salmeron; T B Ahmad; G W Carlile; D Pappin; R P Narsimhan; S C Ley
Journal:  EMBO J       Date:  1996-02-15       Impact factor: 11.598

Review 4.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

5.  The C.elegans MAPK phosphatase LIP-1 is required for the G(2)/M meiotic arrest of developing oocytes.

Authors:  Alex Hajnal; Thomas Berset
Journal:  EMBO J       Date:  2002-08-15       Impact factor: 11.598

6.  A link between MAP kinase and p34(cdc2)/cyclin B during oocyte maturation: p90(rsk) phosphorylates and inactivates the p34(cdc2) inhibitory kinase Myt1.

Authors:  A Palmer; A C Gavin; A R Nebreda
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

7.  Ultrasensitivity in the mitogen-activated protein kinase cascade.

Authors:  C Y Huang; J E Ferrell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

8.  Dependence of Mos-induced Cdc2 activation on MAP kinase function in a cell-free system.

Authors:  C Y Huang; J E Ferrell
Journal:  EMBO J       Date:  1996-05-01       Impact factor: 11.598

9.  Mos is not required for the initiation of meiotic maturation in Xenopus oocytes.

Authors:  Aude Dupré; Catherine Jessus; René Ozon; Olivier Haccard
Journal:  EMBO J       Date:  2002-08-01       Impact factor: 11.598

10.  The membrane immunoglobulin receptor utilizes a Shc/Grb2/hSOS complex for activation of the mitogen-activated protein kinase cascade in a B-cell line.

Authors:  G Kumar; S Wang; S Gupta; A Nel
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.